User-agent: Googlebot
Disallow: /danonehealth-ca
Disallow: /humalog-mix-25-web-banner
Disallow: /humalog-web-banner
Disallow: /never-mind-the-delay-amgen-puts-dmab-on-its-website-2
Disallow: /pfizer-rejoins-pharma-stampede-to-india-2
Disallow: /norlevo-emergency-contraception
Disallow: /2009/12/23/2009-biotech-cheers-and-jeers
Disallow: /2009/12/23/exelixis-inc-warming-up-or-cooling-off
Disallow: /232711-revision-21/uyxz
Disallow: /235892-revision/uyxz
Disallow: /235899-revision-3/uyxz
Disallow: /236116-revision/uyxz
Disallow: /236125-autosave/uyxz
Disallow: /236125-revision-2/uyxz
Disallow: /236145-revision-3/uyxz
Disallow: /236145-revision-4/uyxz
Disallow: /236145-revision-5/uyxz
Disallow: /236150-revision-2/uyxz
Disallow: /236150-revision-3/uyxz
Disallow: /236150-revision-4/uyxz
Disallow: /236150-revision-5/uyxz
Disallow: /236150-revision/uyxz
Disallow: /236160-revision-2/uyxz
Disallow: /236160-revision-3/uyxz
Disallow: /236160-revision/uyxz
Disallow: /236185-revision-5/uyxz
Disallow: /4-winning-biotechs-for-your-portfolio-senior-analyst/uyxz
Disallow: /abbott-completes-acquisition-of-solvay-pharmaceuticals/uyxz
Disallow: /abbott-submits-new-automated-ovarian-cancer-test-for-u-s-approval/uyxz
Disallow: /abcd/
Disallow: /alcon-profit-rises-as-novartis-takeover-looms/uyxz
Disallow: /alex-savic-2/uyxz
Disallow: /alex-savic-ehealth-expert/uyxz
Disallow: /amgen-denosumab-demonstrates-superiority-over-zometa/uyxz
Disallow: /anacor-merck-returns-fungal-infection-drug-rights/uyxz
Disallow: /and-the-future-for-pharma-looks-likea€¦/uyxz
Disallow: /are-the-people-at-astra-zenica-that-clueless/uyxz
Disallow: /as-labopharm-prepares-for-oleptro-launch-it-seeks-20m/uyxz
Disallow: /ask-our-experts/uyxz
Disallow: /astrazeneca-reassures-investors-on-earnings/uyxz
Disallow: /base-hits-vs-home-runs/
Disallow: /biotech-stock-mailbag-nexmed/uyxz
Disallow: /bristol-myers-salary-freeze-affects-only-6-of-ceos-total-pay/uyxz
Disallow: /cadence-why-fda-approval-is-imminent/uyxz
Disallow: /cell-therapeutics-upcoming-fda-worries/uyxz
Disallow: /china-amends-patent-law-for-compulsory-licensing/uyxz
Disallow: /china-biotech-week-in-review/uyxz
Disallow: /cholesterol-cutting-drugs-raise-diabetes-risk-by-9-in-study/uyxz
Disallow: /csl-profit-beats-estimates-on-swine-flu-vaccine-sales/uyxz
Disallow: /cvs-may-get-earnings-a€˜windfalla€™-from-lipitor-plavix-generics/uyxz
Disallow: /despite-ma-slowdown-pharmaceutical-deals-remained-plentiful-in-2009/uyxz
Disallow: /dont-ignore-this-potential-blockbuster-taspoglutide-roche/uyxz
Disallow: /drug-industry-signals-lobbying-shift/uyxz
Disallow: /drug-stocks-slip-shire-climbs-on-earnings-report/uyxz
Disallow: /drug-stocks-that-deserve-a-closer-look/uyxz
Disallow: /drug-stocks-diverge-astrazeneca-declines/uyxz
Disallow: /fda-ad-division-objects-to-user-friendly-efficacy-claims-with-jargon/uyxz
Disallow: /fda-agreements-should-be-public/uyxz
Disallow: /fda-blasts-lillys-pah-ecommunity-videos/uyxz
Disallow: /fda-clears-drug-chief-of-conflict-2/uyxz
Disallow: /fda-raises-concerns-about-cell-therapeutics-cancer-drug/uyxz
Disallow: /former-pfizer-sues-pfizer-over-lipitor-marketing/uyxz
Disallow: /gardens-drug-start-up-finds-success-in-canada-with-safe-dosing-device/uyxz
Disallow: /gsk-rare-diseases-now-big-business/uyxz
Disallow: /i-could-have-been-a-blockbuster/uyxz
Disallow: /imclone-founder-waksal-forming-new-biotech-venture/uyxz
Disallow: /is-the-sec-probing-trading-in-dendreon/uyxz
Disallow: /jim-dayton-new-media-expert/uyxz
Disallow: /john-mack-pharma-marketing-expert/uyxz
Disallow: /large-pharma-and-small-biotech-deals-expected-to-increase-in-2010/uyxz
Disallow: /lilly-pressured-as-its-first-new-drug-in-4-years-falters/uyxz
Disallow: /martek-closes-on-purchase-of-amerifit-brands-inc/uyxz
Disallow: /mccain-moves-to-give-fda-more-authority-over-supplements/uyxz
Disallow: /merck-earnings-preview/uyxz
Disallow: /merck-studies-boost-gardasil-for-new-uses/uyxz
Disallow: /more/in-the-pipeline/ariads-patent-rises-from-the-grave-to-smite-the-living
Disallow: /more/pharma-ads/cardinal-health-goes-digital-with-new-marketing-tool
Disallow: /more/pharma-ads/head-shoulders-austria
Disallow: /more/pharma-ads/inpes-ae%E2%80%9C-sexually-transmitted-diseases-awareness-campaign
Disallow: /more/pharma-ads/pfizer-pays-23-billion-for-deceptive-marketing-practices
Disallow: /more/pharma-ads/topicort
Disallow: /news-2/dainippon-grabs-sepracor-for-26b
Disallow: /obama-takes-new-tack-on-healthcare-reform/uyxz
Disallow: /news-2/court-invalidates-1-of-lillys-gemzar-patents-2
Disallow: /panel-of-experts/experts-panel-of-experts/jae-chung-health-systems-20-expert
Disallow: /perrigo-wins-patent-suit-on-mucinex/uyxz
Disallow: /pfizer-launches-e-payment-system/uyxz
Disallow: /polluting-the-literature-with-pains/uyxz
Disallow: /roche-diabetes-drug-performs-like-a-blockbuster-in-ph3/uyxz
Disallow: /rochea%E2%82%AC%E2%84%A2s-diabetes-drug-meets-goals-in-five-studies/
Disallow: /sanofi-to-decide-soon-on-reviving-merck-venture/uyxz
Disallow: /simcere-wins-ok-for-flu-drug-relenza/uyxz
Disallow: /theravance-misses-estimates/uyxz
Disallow: /together-at-last/uyxz
Disallow: /uk-court-overturns-gsk-patent-for-lupus-drug/uyxz
Disallow: /us-patent-for-avanir-pharmas-low-dose-quinidine-formulations-of-zeniva/uyxz
Disallow: /video-is-biotech-back/uyxz
Disallow: /wp-content/uploads/2010/02/107901.gif/feed/
Disallow: /wp-content/uploads/2010/02/107901.gif/trackback/
Disallow: /wp-content/uploads/2010/02/notice.jpg/feed/
Disallow: /wp-content/uploads/2010/02/notice.jpg/trackback/
Disallow: /wp-content/uploads/2010/02/phishing.jpg/feed/
Disallow: /wp-content/uploads/2010/02/phishing.jpg/trackback/